VIRIDIAN THERAPEUTICS INC(NASDAQ:VRDN) stock News

VRDN Latest News, Press Relases and Analysis

All

Press Releases

22 days ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

3 months ago - By: Benzinga

What 5 Analyst Ratings Have To Say About Viridian Therapeutics

3 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

3 months ago - By: Zacks Investment Research - Mentions: IOVA

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates

3 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

3 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Benzinga

Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts

4 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

5 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

6 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

7 months ago - By: Investor's Business Daily - Mentions: AMGN

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

7 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

7 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

8 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

9 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

11 months ago - By: Viridian Therapeutics, Inc.

VIRIDIAN THERAPEUTICS INC (VRDN) Stock News

VRDN Latest News, Press Relases and Analysis

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

What 5 Analyst Ratings Have To Say About Viridian Therapeutics

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock